EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Phase 1 Completed
11 enrolled
HUMC 1612: Optune NovoTTF-200A System
Phase 1 Completed
7 enrolled 12 charts
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Phase 1 Completed
17 enrolled 11 charts
5-AZA
Phase 1 Completed
3 enrolled
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Phase 1 Completed
29 enrolled
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Phase 1 Completed
8 enrolled 9 charts
COZMOS
Phase 1 Completed
31 enrolled
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Phase 1 Completed
13 enrolled
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
Phase 1 Completed
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase 1 Completed
8 enrolled
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
86 enrolled
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
Phase 1 Completed
12 enrolled
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Phase 1 Completed
22 enrolled
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Phase 1 Completed
81 enrolled
Aflac ST0901
Phase 1 Completed
18 enrolled
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
Phase 1 Completed
9 enrolled
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Phase 1 Completed
28 enrolled
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Phase 1 Completed
5 enrolled
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Phase 1 Completed
3 enrolled
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Phase 1 Completed
12 enrolled
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
Phase 1 Completed
7 enrolled
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Phase 1 Completed
8 enrolled
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
Phase 1 Completed
3 enrolled
SJREFU
Phase 1 Completed
26 enrolled
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase 1 Completed
37 enrolled
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
22 enrolled
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Phase 1 Completed
6 enrolled
CC-5013 in Treating Patients With Recurrent Glioma
Phase 1 Completed
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Phase 1 Completed
10 enrolled
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Phase 1 Completed
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Phase 1 Completed
60 enrolled
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Phase 1 Completed
6 enrolled
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Phase 1 Completed
25 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
Phase 1 Completed
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Phase 1 Completed
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
Carmustine in Treating Patients With Recurrent Malignant Glioma
Phase 1 Completed
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
Phase 1 Completed